Insidious Insights: Implications of Viral Vector Engineering for Pathogen Enhancement

Overview

Journal Gene Ther

Date 2022 Mar 10

PMID 35264741

Authors

Jonas B Sandbrink

Ethan C Alley

Matthew C Watson

Gregory D Koblentz

Kevin M Esvelt

Affiliations

Soon will be listed here.

Abstract

Optimizing viral vectors and their properties will be important for improving the effectiveness and safety of clinical gene therapy. However, such research may generate dual-use insights relevant to the enhancement of pandemic pathogens. In particular, reliable and generalizable methods of immune evasion could increase viral fitness sufficient to cause a new pandemic. High potential for misuse is associated with (1) the development of universal genetic elements for immune modulation, (2) specific insights on capsid engineering for antibody evasion applicable to viruses with pandemic potential, and (3) the development of computational methods to inform capsid engineering. These risks may be mitigated by prioritizing non-viral delivery systems, pharmacological immune modulation methods, non-genetic vector surface modifications, and engineering methods specific to AAV and other viruses incapable of unassisted human-to-human transmission. We recommend that computational vector engineering and the publication of associated code and data be limited to AAV until a technical solution for preventing malicious access to viral engineering tools has been established.

Citing Articles

Vesicular Stomatitis Virus: Insights into Pathogenesis, Immune Evasion, and Technological Innovations in Oncolytic and Vaccine Development.

Ahmed M, Okesanya O, Ukoaka B, Ibrahim A, Lucero-Prisno 3rd D Viruses. 2025; 16(12.

PMID: 39772239 PMC: 11680291. DOI: 10.3390/v16121933.

Bridging biosafety and biosecurity gaps: DURC and ePPP policy insights from U.S. institutions.

Gillum D, Tran A, Fletcher J, Vogel K Front Bioeng Biotechnol. 2024; 12():1476527.

PMID: 39398640 PMC: 11467424. DOI: 10.3389/fbioe.2024.1476527.

Application of Optogenetics in Neurodegenerative Diseases.

Zhang Q, Li T, Xu M, Islam B, Wang J Cell Mol Neurobiol. 2024; 44(1):57.

PMID: 39060759 PMC: 11281982. DOI: 10.1007/s10571-024-01486-1.

Peptosome: A New Efficient Transfection Tool as an Alternative to Liposome.

Manteghi M, Can O, Kocagoz T Int J Mol Sci. 2024; 25(13).

PMID: 39000028 PMC: 11241524. DOI: 10.3390/ijms25136918.

Beyond Biosecurity by Taxonomic Lists: Lessons, Challenges, and Opportunities.

Millett P, Alexanian T, Brink K, Carter S, Diggans J, Palmer M Health Secur. 2023; 21(6):521-529.

PMID: 37856148 PMC: 10733751. DOI: 10.1089/hs.2022.0109.

References

Baek M, DiMaio F, Anishchenko I, Dauparas J, Ovchinnikov S, Lee G . Accurate prediction of protein structures and interactions using a three-track neural network. Science. 2021; 373(6557):871-876. PMC: 7612213. DOI: 10.1126/science.abj8754. View

Manservigi R, Argnani R, Marconi P . HSV Recombinant Vectors for Gene Therapy. Open Virol J. 2010; 4:123-56. PMC: 2936037. DOI: 10.2174/1874357901004030123. View

Denniston E, Crewdson H, Rucinsky N, Stegman A, Remenar D, Moio K . The Practical Consideration of Poliovirus as an Oncolytic Virotherapy. Am J Virol. 2017; 5(1):1-7. PMC: 5304422. DOI: 10.3844/ajvsp.2016.1.7. View

Ahn K, Gruhler A, Galocha B, Jones T, Wiertz E, Ploegh H . The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity. 1997; 6(5):613-21. DOI: 10.1016/s1074-7613(00)80349-0. View

Kim M, Jeong M, Hur S, Cho Y, Park J, Jung H . Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci Adv. 2021; 7(9). PMC: 7909888. DOI: 10.1126/sciadv.abf4398. View

Chan Y, Wang S, Chu C, Copland D, Letizia A, Costa Verdera H . Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses. Sci Transl Med. 2021; 13(580). PMC: 8409505. DOI: 10.1126/scitranslmed.abd3438. View

Pizzuto M, Silic-Benussi M, Ciminale V, Elderfield R, Capua I, Barclay W . An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy. J Gen Virol. 2016; 97(9):2166-2179. DOI: 10.1099/jgv.0.000549. View

Singh R, Tian B, Kostarelos K . Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. FASEB J. 2008; 22(9):3389-402. DOI: 10.1096/fj.08-103275. View

Sandbrink J, Koblentz G . Biosecurity risks associated with vaccine platform technologies. Vaccine. 2021; 40(17):2514-2523. PMC: 7904460. DOI: 10.1016/j.vaccine.2021.02.023. View

10.

Adriouch S, Franck E, Drouot L, Bonneau C, Jolinon N, Salvetti A . Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. Front Microbiol. 2011; 2:199. PMC: 3202221. DOI: 10.3389/fmicb.2011.00199. View

11.

Shahryari A, Jazi M, Mohammadi S, Nikoo H, Nazari Z, Hosseini E . Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Front Genet. 2019; 10:868. PMC: 6773888. DOI: 10.3389/fgene.2019.00868. View

12.

Bryant D, Bashir A, Sinai S, Jain N, Ogden P, Riley P . Deep diversification of an AAV capsid protein by machine learning. Nat Biotechnol. 2021; 39(6):691-696. DOI: 10.1038/s41587-020-00793-4. View

13.

Meier A, Fraefel C, Seyffert M . The Interplay between Adeno-Associated Virus and its Helper Viruses. Viruses. 2020; 12(6). PMC: 7354565. DOI: 10.3390/v12060662. View

14.

Yu B, Zhou Y, Wu H, Wang Z, Zhan Y, Feng X . Seroprevalence of neutralizing antibodies to human adenovirus type 5 in healthy adults in China. J Med Virol. 2012; 84(9):1408-14. DOI: 10.1002/jmv.23325. View

15.

Arze C, Springer S, Dudas G, Patel S, Bhattacharyya A, Swaminathan H . Global genome analysis reveals a vast and dynamic anellovirus landscape within the human virome. Cell Host Microbe. 2021; 29(8):1305-1315.e6. DOI: 10.1016/j.chom.2021.07.001. View

16.

Msaouel P, Iankov I, Dispenzieri A, Galanis E . Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol. 2011; 13(9):1732-41. PMC: 3298624. DOI: 10.2174/138920112800958896. View

17.

Gilsdorf J, Zilinskas R . New considerations in infectious disease outbreaks: the threat of genetically modified microbes. Clin Infect Dis. 2005; 40(8):1160-5. DOI: 10.1086/428843. View

18.

Wec A, Lin K, Kwasnieski J, Sinai S, Gerold J, Kelsic E . Overcoming Immunological Challenges Limiting Capsid-Mediated Gene Therapy With Machine Learning. Front Immunol. 2021; 12:674021. PMC: 8112259. DOI: 10.3389/fimmu.2021.674021. View

19.

Meliani A, Boisgerault F, Fitzpatrick Z, Marmier S, Leborgne C, Collaud F . Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors. Blood Adv. 2018; 1(23):2019-2031. PMC: 5728288. DOI: 10.1182/bloodadvances.2017010181. View

20.

Ahn K, Meyer T, Uebel S, SEMPE P, Djaballah H, Yang Y . Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. EMBO J. 1996; 15(13):3247-55. PMC: 451885. View